Moreau, Philippe <br/><br/>
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.  [electronic resource] 

 -  The Lancet. Oncology  May 2011 
 - 431-40 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(11)70081-X  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Asia<br/>Blood Cells--drug effects<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Europe<br/>Humans<br/>Infusions, Intravenous<br/>Injections, Subcutaneous<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--blood<br/>Neoplasm Staging<br/>Peripheral Nervous System Diseases--chemically induced<br/>Protease Inhibitors--administration & dosage<br/>Pyrazines--administration & dosage<br/>Recurrence<br/>South America<br/>Treatment Outcome